Iodine(III)-Mediated Construction of Dibenzoxazepinone Skeleton from 2-(Aryloxy)benzamides through Oxidative C-N Formation

Xuliang Guo,[†] Daisy Zhang-Negrerie,[†] and Yunfei Du*,^{†,‡}

 [†]Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
[‡]Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300072, China

duyunfeier@tju.edu.cn

Supporting Information

	Page
I. General Information	S 1
II. Preparation and Characterization Data of Amides 1	S1-S9
III. Preparation of 2a-m and 2q	S10
IV. Preparation of 2a-m , 2q and Characterization Data of Compounds 2	S10-
S17	
V. References	S17-
S18	
VI. ¹ H-NMR. ¹³ C-NMR and ¹⁹ F-NMR Spectra	S19-S89

I. General Information

All reactions were carried out at room temperature under air unless otherwise noted. ¹H and ¹³C NMR spectra were recorded on 600 MHz or 400 MHz spectrometer at 25 °C. Chemical shifts values are given in ppm and referred as the internal standard to TMS: 0.00 ppm. The peak patterns are indicated as follows: s, singlet; d, doublet; t, triplet; q, quartet; qui, quintet; m, multiplet and dd, doublet of doublets, brs, broad singlet. The coupling constants *J*, are reported in Hertz (Hz). High resolution mass spectrometry (HRMS) was obtained on a Q-TOF micro spectroMeter. Melting points were determined with a MicroMelting point apparatus without corrections. Organic solutions were concentrated by rotary evaporation below 40 °C in vacuum. TLC plates were visualized by exposure to ultraviolet light.

Reagents and solvents were purchased as reagent grade and were used without further purification. All reactions were performed in standard glassware, heated at 70 °C for 3 h before use. Flash column chromatography was performed over silica gel 200-300 m and the eluent was a mixture of ethyl acetate (EA) and petroleum ether (PE).

II. Procedures for the Synthesis of Amides 1.¹⁻³

1. General Procedure for the Synthesis of Acids 3a-p and 3r.



To a mixture of substituted 2-bromobenzoic ester (10 mmol) and substitutedphenol (12 mmol) in toluene (20 mL) was added Cs_2CO_3 (3.78 g, 15 mmol) and CuI (1.90 g 10 mmol) and the flask was purged with N₂. After stirring for 5 minutes at room temperature, the mixture was stirred at 125 °C for 15 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was cooled down to room temperature, filtered over celite, washed with ethyl acetate, and evaporated. To the crude material was added MeOH (40 mL), KOH (2.8 g) and the mixture was stirred for 3 hours at 45 °C. After completion of the hydrolysis, aq. HCl solution (3 M, 45

mL) was used to adjust pH to 3-4. Then extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude product can be used for the next step without any purification.

2. Procedure for the Synthesis of Acid 3q.



2-Bromobenzoic acid (2.0 g, 10 mmol), 4-nitrophenol (1.4 g, 10 mmol), *N*-methylmorpholine (1.7 mL, 15 mmol) and Cu(I) oxide (0.72 g, 5 mmol) were heated to reflux in dioxane (30 mL) under nitrogen for 16 h. The resulting reaction mixture was allowed to cool slowly to room temperature before HCl (4 M, 20 mL) was added. The precipitate was filtrated, washed with water (10 mL \times 2), and then concentrated under reduced pressure.⁴

3. General Procedure for Converting Acids 3a-r into Amides 1a-r.



To a solution of the substituted 2-bromobenzoic acid in DCM (0.3 M) was added a catalytic amount of DMF (2 drops). At ambient temperature, oxalyl chloride (1.2 equiv) was added dropwise over a period of 0.5 h. The resulting solution was kept at room temperature until TLC indicated the total consumption of the acid. Then, the solvent was removed under reduced pressure. The residue was dissolved in dry DCM (5 mL) and slowly added dropwise to a solution of the NH₂OMe·HCl (1.2 equiv) and K_2CO_3 (3 equiv) in EA/H₂O = 2:1 (40 mL). The reaction mixture was maintained at ambient temperature and monitored by TLC. Upon completion, the mixture was

extracted with EA (3 \times 50 mL) and the combined organic phase was washed with NH₄Cl (80 mL) and brine (80 mL). Dried over Na₂SO₄ and evaporation of the solvent under reduced pressure and purification of the crude residue by flash column chromatography on silica gel (EA/PE) afforded the desired amides.

<u>N-Methoxy-2-phenoxybenzamide (1a)</u>



Following the general procedure, **1a** was obtained as a white solid (1.34 g), yield: 55% (over three steps), mp. 66 – 68 °C. ¹H NMR (600 MHz, CDCl₃) δ 10.10 (s, 1H), 8.25 (d, *J* = 7.2 Hz, 1H), 7.44 – 7.40 (m, 2H), 7.40 – 7.36 (m, 1H), 7.26 – 7.18 (m, 2H), 7.10 – 7.05 (m, 2H), 6.81 – 6.76 (d, *J* = 8.3 Hz, 1H), 3.86 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 163.6, 155.5, 154.9, 133.2, 132.2, 130.3, 125.2, 123.6, 121.6, 120.1, 117.6, 64.5; HRMS (ESI) calcd for C₁₄H₁₃NNaO₃⁺ [M + Na⁺] 266.0788, found 266.0790.

N-Methoxy-5-methyl-2-phenoxybenzamide (1b)



Following the general procedure, **1b** was obtained as a light yellow oil (1.16 g), yield: 45% (over three steps). ¹H NMR (600 MHz, CDCl₃) δ 10.08 (s, 1H), 8.03 (s, 1H), 7.39 (dd, J = 8.3, 7.7 Hz, 2H), 7.24 – 7.15 (m, 2H), 7.04 (d, J = 7.8 Hz, 2H), 6.71 (d, J = 8.4 Hz, 1H), 3.83 (s, 3H), 2.36 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 163.7, 155.5, 153.0, 133.8, 133.6, 132.2, 130.2, 124.8, 121.5, 119.6, 118.2, 64.5, 20.5; HRMS (ESI) calcd for C₁₅H₁₅NNaO₃⁺ [M + Na⁺] 280.0944, found 280.0947.

5-Bromo-N-methoxy-2-phenoxybenzamide (1c)



Following the general procedure, **1c** was obtained as light yellow oil (1.67 g), yield: 52% (over three steps).¹H NMR (600 MHz, CDCl₃) δ 10.10 (s, 1H), 8.35 (s, 1H), 7.50 – 7.38 (m, 3H), 7.30 – 7.25 (m, 1H), 7.07 (d, J = 8.0 Hz, 2H), 6.67 (d, J = 8.8 Hz, 1H), 3.85 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 163.4, 154.9, 154.3, 133.3, 132.3, 124.1, 122.0, 121.6, 117.8, 64.6; HRMS (ESI) calcd for C₁₄H₁₂⁷⁹BrNNaO₃⁺ [M + Na⁺] 343.9893, found 343.9895.

5-Fluoro-N-methoxy-2-phenoxybenzamide (1d)



Following the general procedure, **1d** was obtained as a light yellow oil (1.17 g), yield: 45% (over three steps). ¹H NMR (600 MHz, CDCl₃) δ 10.11 (s, 1H), 7.94 (dd, J = 9.0, 3.0 Hz, 1H), 7.47 – 7.35 (m, 2H), 7.23 (t, J = 7.4 Hz, 1H), 7.09 (ddd, J = 9.1, 7.1, 3.3 Hz, 1H), 7.06 – 7.03 (m, 2H), 6.79 (dd, J = 9.0, 4.3 Hz, 1H), 3.84 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 162.2 , 158.6 (d, $J_{C-F} = 243.9$ Hz), 155.3 , 151.3 , 130.4 , 125.2 , 123.5 (d, $J_{C-F} = 7.4$ Hz), 120.0 (d, $J_{C-F} = 23.9$ Hz), 119.7 (d, $J_{C-F} = 7.6$ Hz), 119.6 , 118.3 (d, $J_{C-F} = 25.4$ Hz), 64.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -118.48 (s, 1F); HRMS (ESI) calcd for C₁₄H₁₂¹⁹FNNaO₃⁺ [M + Na⁺] 284.0693, found 284.0692.

4-Chloro-N-methoxy-2-phenoxybenzamide (1e)



Following the general procedure, **1e** was obtained as a light yellow oil (1.39 g), yield: 50% (over three steps). ¹H NMR (600 MHz, CDCl₃) δ 10.04 (s, 1H), 8.20 (d, *J* = 8.4 Hz, 1H), 7.46 (t, *J* = 7.8 Hz, 2H), 7.30 (t, *J* = 7.4 Hz, 1H), 7.22 – 7.15 (m, 1H), 7.10 (d, *J* = 8.3 Hz, 2H), 6.74 (s, 1H), 3.87 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ

162.7, 156.2, 154.1, 138.9, 133.4, 130.4, 125.9, 123.8, 120.4, 119.8, 117.3, 64.6; HRMS (ESI) calcd for $C_{14}H_{12}{}^{35}CINNaO_{3}{}^{+}$ [M + Na⁺] 300.0398, found 300.0398.

2-(4-Bromophenoxy)-5-fluoro-N-methoxybenzamide (1f)



Following the general procedure, **1f** was obtained as a white solid (1.64 g), yield: 48% (over three steps), mp. 106 – 108 °C. ¹H NMR (600 MHz, CDCl₃) δ 9.96 (s, 1H), 7.91 (d, *J* = 8.9 Hz, 1H), 7.52 (dd, *J* = 8.1, 3.4 Hz, 2H), 7.17 – 7.05 (m, 1H), 6.93 (d, *J* = 8.7 Hz, 2H), 6.80 (dd, *J* = 8.9, 4.0 Hz, 1H), 3.84 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 162.0, 158.8 (d, *J*_{C-F} = 244.7 Hz), 154.6, 150.6, 133.36, 123.9 (d, *J*_{C-F} = 7.1 Hz), 121.1, 120.1 (d, *J*_{C-F} = 23.8 Hz), 119.9 (d, *J*_{C-F} = 7.7 Hz), 118.4 (d, *J*_{C-F} = 25.2 Hz), 117.9, 64.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -117.46 (s, 1F); HRMS (ESI) calcd for C₁₄H₁₁⁷⁹Br¹⁹FNNaO₃⁺ [M + Na⁺] 361.9799, found 361.9802.

2-(4-Bromophenoxy)-N-methoxybenzamide (1g)



Following the general procedure, **1g** was obtained as a beige solid (1.51 g), yield: 47% (over three steps), mp. 88 – 90 °C. ¹H NMR (600 MHz, CDCl₃) δ 9.96 (s, 1H), 8.23 (d, J = 7.7 Hz, 1H), 7.53 (d, J = 8.7 Hz, 2H), 7.46 – 7.36 (m, 1H), 7.24 (t, J = 7.6 Hz, 1H), 6.96 (d, J = 8.8 Hz, 2H), 6.79 (d, J = 8.3 Hz, 1H), 3.86 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 163.4, 154.9, 154.3, 133.3, 132.3, 124.1, 122.0, 121.6, 117.8, 64.6 (one carbon peak was missing due to overlapping); HRMS (ESI) calcd for C₁₄H₁₁⁷⁹Br¹⁹FNNaO₃⁺ [M + Na⁺] 361.9799, found 361.9801.

2-(4-Chlorophenoxy)-N-methoxybenzamide (1h)



Following the general procedure, **1h** was obtained as a white solid (1.33 g), yield: 48% (over three steps), mp. 86 – 88 °C. ¹H NMR (600 MHz, CDCl₃) δ 9.92 (s, 1H), 8.22 (d, *J* = 7.5 Hz, 1H), 7.42 – 7.39 (m, 1H), 7.38 – 7.35 (m, 2H), 7.25 – 7.21 (m, 1H), 7.09 – 6.92 (m, 2H), 6.79 (d, *J* = 8.2 Hz, 1H), 3.86 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 163.4, 154.9, 153.80, 133.2, 132.1, 130.2, 130.2, 124.0, 122.2, 121.1, 117.9, 64.4; HRMS (ESI) calcd for C₁₄H₁₂³⁵ClNNaO₃⁺ [M + Na⁺] 300.0398, found 300.0396

5-Bromo-2-(4-bromophenoxy)-N-methoxybenzamide (1i)



Following the general procedure, **1i** was obtained as a white solid (1.56 g), yield: 39% (over three steps), mp. 77 – 79 °C. ¹H NMR (600 MHz, CDCl₃) δ 8.05 (d, *J* = 2.5 Hz, 1H), 7.58 (dd, *J* = 8.7, 2.5 Hz, 1H), 7.47 – 7.38 (m, 2H), 6.87 (d, *J* = 8.7 Hz, 1H), 6.84 – 6.79 (m, 2H), 3.82 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 162.0, 154.1, 153.8, 136.0, 134.9, 133.5, 123.4, 121.7, 119.4, 118.4, 116.9, 64.6; HRMS (ESI) calcd for C₁₄H₁₁⁷⁹Br₂NNaO₃⁺ [M + Na⁺] 421.8998, found 421.9001.

2-(4-Bromophenoxy)-4-chloro-N-methoxybenzamide (1j)



Following the general procedure, **1j** was obtained as a white solid (1.28 g), yield: 36% (over three steps), mp. 116 – 118 °C. ¹H NMR (600 MHz, CDCl₃) δ 9.90 (s, 1H), 8.17 (d, *J* = 8.4 Hz, 1H), 7.57 (d, *J* = 8.8 Hz, 2H), 7.20 (dd, *J* = 8.5, 1.9 Hz, 1H), 6.99 (d, *J* = 8.8 Hz, 2H), 6.74 (d, *J* = 1.7 Hz, 1H), 3.86 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 162.5, 155.6, 153.3, 139.0, 133.6, 133.5, 124.3, 122.1, 120.1, 118.8, 117.4, 64.6; HRMS (ESI) calcd for C₁₄H₁₁⁷⁹Br³⁵ClNNaO₃⁺ [M + Na⁺] 377.9503, found 377.9504.

2-(4-Bromophenoxy)-N-methoxy-5-methylbenzamide (1k)



Following the general procedure, **1k** was obtained as a tan solid (1.71 g), yield: 51% (over three steps), mp. 62 – 64 °C. ¹H NMR (600 MHz, CDCl₃) δ 9.91 (s, 1H), 8.01 (s, 1H), 7.49 (d, *J* = 8.8 Hz, 2H), 7.24 – 7.16 (m, 1H), 6.92 (d, *J* = 8.8 Hz, 2H), 6.71 (d, *J* = 8.4 Hz, 1H), 3.83 (s, 3H), 2.37 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 163.5, 154.9, 152.4, 134.2, 133.9, 133.1, 132.3, 121.9, 121.0, 118.4, 117.3, 64.5, 20.5; HRMS (ESI) calcd for C₁₅H₁₄⁷⁹BrNNaO₃⁺ [M + Na⁺] 358.0049, found 358.0047.

4-Chloro-2-(4-chlorophenoxy)-N-methoxybenzamide (11)



Following the general procedure, **11** was obtained as a white solid (1.25 g), yield: 40% (over three steps), mp. 63 – 65 °C. ¹H NMR (600 MHz, CDCl₃) δ 9.97 (s, 1H), 8.12 (d, J = 7.8 Hz, 1H), 7.40 (d, J = 8.3 Hz, 2H), 7.18 (d, J = 8.4 Hz, 1H), 7.05 (d, J = 8.2 Hz, 2H), 6.74 (s, 1H), 3.84 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 162.5, 155.7, 152.9, 138.9, 133.3, 131.1, 130.5, 124.2, 121.6, 120.3, 117.5, 64.5; HRMS (ESI) calcd for C₁₄H₁₁³⁵Cl₂NNaO₃⁺ [M + Na⁺] 334.0008, found 334.0010.

2-(4-Chlorophenoxy)-N-methoxy-5-methylbenzamide (1m)



Following the general procedure, **1m** was obtained as a white solid (1.49 g), yield: 51%, mp. 62 – 64 °C. ¹H NMR (600 MHz, CDCl₃) δ 9.99 (s, 1H), 7.98 (s, 1H), 7.41 – 7.31 (m, 2H), 7.21 (d, *J* = 8.4 Hz, 1H), 7.05 – 6.91 (m, 2H), 6.71 (d, *J* = 8.3 Hz, 1H), 3.83 (s, 3H), 2.36 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 163.5, 154.3, 152.5, 134.1, 133.9, 132.2, 130.1, 129.8, 121.8, 120.7, 118.3, 64.5, 20.5; HRMS (ESI) calcd for C₁₅H₁₄³⁵ClNNaO₃⁺ [M + Na⁺] 314.0554, found 314.0557.

<u>N-Methoxy-2-(p-tolyloxy)benzamide (1n)</u>



Following the general procedure, **1n** was obtained as a beige solid (1.39 g), yield: 54%, mp. 96 – 98 °C. ¹H NMR (600 MHz, CDCl₃) δ 10.18 (s, 1H), 8.24 (d, *J* = 7.7 Hz, 1H), 7.40 – 7.32 (m, 1H), 7.21 (d, *J* = 8.1 Hz, 2H), 7.18 (t, *J* = 7.6 Hz, 1H), 6.97 (d, *J* = 8.4 Hz, 2H), 6.76 (d, *J* = 8.3 Hz, 1H), 3.87 (s, 3H), 2.37 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 163.7, 156.0, 152.5, 135.0, 133.1, 132.2, 130.8, 123.3, 121.2, 120.2, 117.1, 64.5, 20.8; HRMS (ESI) calcd for C₁₅H₁₅NNaO₃⁺ [M + Na⁺] 280.0944, found 280.0943.

2-(2,3-Dimethylphenoxy)-N-methoxybenzamide (10)



Following the general procedure, **10** was obtained as a brown solid (1.02 g), yield: 37%, mp. 104 – 106 °C. ¹H NMR (600 MHz, CDCl₃) δ 10.32 (s, 1H), 8.27 (dd, J =7.8, 1.6 Hz, 1H), 7.32 (ddd, J = 8.4, 7.4, 1.8 Hz, 1H), 7.20 – 7.06 (m, 3H), 6.86 (d, J =7.8 Hz, 1H), 6.56 (dd, J = 8.3, 0.6 Hz, 1H), 3.90 (s, 3H), 2.35 (s, 3H), 2.12 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 163.8, 156.2, 152.0, 139.6, 133.2, 132.3, 129.2, 127.4, 126.9, 122.7, 120.1, 118.9, 115.3, 64.6, 20.1, 12.4; HRMS (ESI) calcd for C₁₆H₁₇NNaO₃⁺ [M + Na⁺] 294.1101, found 294.1103.

N-Methoxy-3-phenoxythiophene-2-carboxamide (1p)



Following the general procedure, **1p** was obtained as a light yellow oil (1.27 g), yield: 37%, mp. ¹H NMR (600 MHz, CDCl₃) δ 9.64 (s, 1H), 7.41 (t, *J* = 7.7 Hz, 3H), 7.23 (t, *J* = 7.4 Hz, 1H), 7.12 (d, *J* = 8.1 Hz, 2H), 6.53 (d, *J* = 5.5 Hz, 1H), 3.85 (s,

3H).¹³C NMR (150 MHz, CDCl₃) δ 160.3, 155.9, 153.5, 130.2, 130.0, 125.3, 119.2, 118.1, 64.9 (one carbon peak was missing due to overlapping); HRMS (ESI) calcd for C₁₂H₁₁NNaO₃S⁺ [M + Na⁺] 272.0352, found 272.0355.

N-Methoxy-2-(4-nitrophenoxy)benzamide (1q)



Following the general procedure, **1q** was obtained as a beige solid (1.12 g), yield: 41%, mp. 108 – 110 °C. ¹H NMR (600 MHz, CDCl₃) δ 9.51 (s, 1H), 8.27 (d, *J* = 9.1 Hz, 2H), 8.16 (d, *J* = 6.3 Hz, 1H), 7.58 – 7.46 (m, 1H), 7.37 (t, *J* = 7.5 Hz, 1H), 7.11 (d, *J* = 9.1 Hz, 2H), 6.97 (d, *J* = 8.2 Hz, 1H), 3.79 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 163.0, 161.3, 152.6, 143.9, 133.5, 132.2, 126.2, 125.9, 123.9, 120.2, 118.3, 64.6; HRMS (ESI) calcd for C₁₄H₁₂N₂NaO₅⁺ [M + Na⁺] 311.0638, found 311.0637.

<u>N-Methoxy-2-(4-methoxyphenoxy)benzamide (1r)</u>



Following the general procedure, **1r** was obtained as a beige solid (1.47 g), yield: 54%, mp. 88 – 90 °C. ¹H NMR (600 MHz, CDCl₃) δ 10.24 (s, 1H), 8.24 (s, 1H), 7.35 (dd, J = 3.0, 1.8 Hz, 1H), 7.23 – 7.10 (m, 1H), 7.03 (dd, J = 8.7, 4.5 Hz, 2H), 6.98 – 6.90 (m, 2H), 6.76 – 6.66 (m, 1H), 3.89 (s, 3H), 3.83 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 163.7, 157.1, 156.6, 147.8, 133.1, 132.2, 123.0, 121.7, 120.7, 116.4, 115.3, 64.6, 55.7; HRMS (ESI) calcd for C₁₅H₁₅NNaO₄⁺ [M + Na⁺] 296.0893, found 296.0896.

III. General Procedure for the Synthesis of 2a-m and 2q.



To a stirred solution of 1 (0.5 mmol) in TFE (10 mL) was added PIDA (1.2 mmol) slowly at room temperature. The resulting mixture was kept at the same temperature until the TLC indicated that the total consumption of 1. The reaction was quenched by sat. NaHCO₃ (25 mL) and extracted with ethyl acetate (3×20 mL). The combined organic layer was washed with brine and dried over anhydrous Na₂SO₄ and then evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel to afford the desired product **2**.

IV. Procedures for the synthesis of 2n-p and 2r



To a stirred solution of 1 (0.5 mmol) in TFE (10 mL) was added PhIO (2.2 mmol) slowly at rt. The resulting mixture was heat at reflux for 15 hours. The reaction was quenched by sat. NaHCO₃ (25 mL) and extracted with ethyl acetate (3×20 mL). The combined organic layer was washed with brine and dried over anhydrous Na₂SO₄

10-Methoxydibenzo[b,f][1,4]oxazepin-11(10H)-one (2a)



Following the general procedure, **2a** was obtained as a light yellow oil (108 mg), yield: 89%. ¹H NMR (600 MHz, CDCl₃) δ 7.89 (dd, J = 7.8, 1.6 Hz, 1H), 7.45 (dd, J = 8.0, 1.6 Hz, 1H), 7.40 (td, J = 8.0, 1.7 Hz, 1H), 7.20 – 7.17 (m, 1H), 7.16 (dd, J = 8.2, 2.1 Hz, 2H), 7.14 – 7.13 (m, 1H), 7.10 (td, J = 7.7, 1.6 Hz, 1H), 3.84 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 162.6, 159.8, 151.4, 134.2, 132.7, 132.2, 127.0, 126.0, 125.4, 124.5, 121.2, 120.5, 120.4, 62.7; HRMS (ESI) calcd for C₁₄H₁₁NNaO₃⁺ [M + Na⁺] 264.0631, found 264.0633.

10-Methoxy-2-methyldibenzo[b,f][1,4]oxazepin-11(10H)-one (2b)



Following the general procedure, **2b** was obtained as a light yellow oil (120 mg), yield: 93%. ¹H NMR (600 MHz, CDCl₃) δ 7.75 (s, 1H), 7.52 (dd, J = 8.0, 1.2 Hz, 1H), 7.27 (s, 1H), 7.26 – 7.24 (m, 1H), 7.22 (td, J = 7.8, 1.4 Hz, 1H), 7.17 (dd, J = 7.7, 1.3 Hz, 1H), 7.10 (d, J = 8.2 Hz, 1H), 3.92 (s, 3H), 2.32 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 162.8, 157.748, 151.7, 135.2, 134.8, 132.7, 132.1, 127.0, 125.9, 124.0, 121.1, 120.6, 120.1, 62.6, 20.6; HRMS (ESI) calcd for C₁₅H₁₃NNaO₃⁺ [M + Na⁺] 278.0788, found 278.0786.

2-Bromo-10-methoxydibenzo[b,f][1,4]oxazepin-11(10H)-one (2c)



Following the general procedure, **2c** was obtained as a light yellow oil (152 mg), yield: 95%. ¹H NMR (600 MHz, CDCl₃) δ 8.08 (d, J = 2.4 Hz, 1H), 7.58 (dd, J = 8.6, 2.4 Hz, 1H), 7.54 (d, J = 8.2 Hz, 1H), 7.27 – 7.24 (m, 2H), 7.21 (dd, J = 10.9, 4.3 Hz, 1H), 7.11 (d, J = 8.6 Hz, 1H), 3.92 (s, 3H).¹³C NMR (150 MHz, CDCl₃) δ 161.3, 158.8, 151.2, 136.9, 134.7, 132.3, 127.3, 126.3, 126.2, 122.3, 121.1, 120.7, 118.3, 62.8; HRMS (ESI) calcd for C₁₄H₁₀⁷⁹BrNNaO₃⁺ [M + Na⁺] 341.9736, found 341.9739.

2-Fluoro-10-methoxydibenzo[b,f][1,4]oxazepin-11(10H)-one (2d)



Following the general procedure, **2d** was obtained as a white solid (117 mg), yield: 89%, mp. 127 – 129 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.65 (dd, J = 8.5, 2.3 Hz, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.28 – 7.24 (m, 2H), 7.19 (ddd, J = 6.2, 4.2, 3.7 Hz, 3H), 3.93 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 161.5 , 159.5 (d, J_{C-F} = 245.0 Hz), 155.7 (d, J_{C-F} = 2.6 Hz), 151.5 , 132.4 , 127.3 , 126.2 , 126.0 (d, J_{C-F} = 7.9 Hz), 122.0 (d, J_{C-F} F = 8.1 Hz), 121.1 , 120.9 (d, J_{C-F} = 23.7 Hz), 120.7 , 118.2 (d, J_{C-F} = 25.5 Hz), 62.7; ¹⁹F NMR (376 MHz, CDCl₃) δ -116.54 (s, 1F); HRMS (ESI) calcd for C₁₄H₁₀¹⁹FNNaO₃⁺ [M + Na⁺] 282.0537, found 282.0540.

<u>3-Chloro-10-methoxydibenzo[*b*,*f*][1,4]oxazepin-11(10*H*)-one (2e)</u>



Following the general procedure, **2e** was obtained as a beige solid (133 mg), yield: 96%, mp. 107 – 109 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.93 (d, *J* = 8.4 Hz, 1H), 7.54 (dd, *J* = 8.4, 1.5 Hz, 1H), 7.27 (ddd, *J* = 8.3, 3.6, 1.7 Hz, 3H), 7.22 (ddd, *J* = 9.2, 8.0, 2.1 Hz, 2H), 3.92 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 161.8, 159.9, 150.9, 139.7, 133.2, 132.5, 127.2, 126.4, 125.9, 123.0, 121.2, 120.9, 120.6, 62.7; HRMS (ESI) calcd for C₁₄H₁₀³⁵CINNaO₃⁺ [M + Na⁺] 298.0241, found 298.0243. 8-Bromo-2-fluoro-10-methoxydibenzo[b,f][1,4]oxazepin-11(10H)-one (2f)



Following the general procedure, **2f** was obtained as a colorless oil (135 mg), yield: 80%. ¹H NMR (600 MHz, CDCl₃) δ 7.71 – 7.58 (m, 2H), 7.30 (d, *J* = 8.3 Hz, 1H), 7.20 (d, *J* = 5.0 Hz, 2H), 7.14 (d, *J* = 8.6 Hz, 1H), 3.95 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 161.3 , 159.6 (d, *J*_{C-F} = 245.6 Hz), 155.3 (d, *J*_{C-F} = 2.4 Hz), 150.1 , 133.8 , 130.0 , 125.5 (d, *J*_{C-F} = 7.9 Hz), 123.4 , 122.6 , 122.0 (d, *J*_{C-F} = 8.1 Hz), 121.3 (d, *J*_{C-F} = 23.7 Hz), 118.9 , 118.3 (d, *J*_{C-F} = 25.5 Hz), 63.1; ¹⁹F NMR (376 MHz, CDCl₃) δ -115.94 (s, 1F); HRMS (ESI) calcd for C₁₄H₉⁷⁹Br¹⁹FNNaO₃⁺ [M + Na⁺] 359.9642, found 359.9645.

8-Bromo-10-methoxydibenzo[b,f][1,4]oxazepin-11(10H)-one (2g)



Following the general procedure, **2g** was obtained as a light yellow solid (146 mg), yield: 91%, mp. 66 – 68 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.98 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.68 (d, *J* = 2.3 Hz, 1H), 7.59 – 7.46 (m, 1H), 7.31 – 7.26 (m, 2H), 7.21 (d, *J* = 8.1 Hz, 1H), 7.15 (d, *J* = 8.6 Hz, 1H), 3.95 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 162.4, 159.3, 150.2, 134.5, 134.2, 132.3, 129.7, 125.7, 124.1, 123.3, 122.7, 120.3, 118.7, 63.1; HRMS (ESI) calcd for C₁₄H₁₀⁷⁹BrNNaO₃⁺ [M + Na⁺] 341.9736, found 341.9734.

8-Chloro-10-methoxydibenzo[b,f][1,4]oxazepin-11(10H)-one (2h)



Following the general procedure, **2h** was obtained as a reddish-brown oil (126 mg), yield: 91%. ¹H NMR (600 MHz, CDCl₃) δ 8.00 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.54 (t, *J* =

2.8 Hz, 1H), 7.52 (dd, J = 7.7, 1.2 Hz, 1H), 7.29 (dd, J = 5.6, 2.3 Hz, 1H), 7.25 – 7.19 (m, 2H), 7.15 (dd, J = 8.6, 2.4 Hz, 1H), 3.97 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 162.4, 159.4, 149.6, 134.4, 133.9, 132.3, 131.4, 126.7, 125.6, 124.1, 122.3, 120.3, 120.3, 63.0; HRMS (ESI) calcd for C₁₄H₁₀³⁵ClNNaO₃⁺ [M + Na⁺] 298.0241, found 298.0238.

2,8-Dibromo-10-methoxydibenzo[b,f][1,4]oxazepin-11(10H)-one (2i)



Following the general procedure, **2i** was obtained as a beige solid (147 mg), yield: 74%. ¹H NMR (600 MHz, CDCl₃) δ 8.08 (s, 1H), 7.68 (d, *J* = 2.3 Hz, 1H), 7.60 (dd, *J* = 8.6, 2.5 Hz, 1H), 7.31 (dd, *J* = 8.6, 2.3 Hz, 1H), 7.11 (dd, *J* = 8.5, 8.6 Hz, 2H), 3.94 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 161.1, 158.3, 149.9, 137.2, 134.8, 133.8, 130.0, 125.8, 123.4, 122.6, 122.2, 119.1, 118.6, 63.1; HRMS (ESI) calcd for C₁₄H₉⁷⁹Br₂NNaO₃⁺ [M + Na⁺] 419.8841, found 419.8844.

8-Bromo-3-chloro-10-methoxydibenzo[b,f][1,4]oxazepin-11(10H)-one (2j)



Following the general procedure, **2j** was obtained as a white solid (133 mg), yield: 75%, mp. 121 – 123 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.98 – 7.88 (m, 1H), 7.73 – 7.64 (m, 1H), 7.34 – 7.28 (m, 1H), 7.26 – 7.21 (m, 2H), 7.13 (dd, *J* = 8.6, 1.4 Hz, 1H), 3.94 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 161.6, 159.5, 149.6, 140.1, 134.0, 133.3, 129.9, 126.1, 123.3, 122.6, 122.6, 120.9, 119.1, 63.1; HRMS (ESI) calcd for C₁₄H₉⁷⁹Br³⁵CINNaO₃⁺ [M + Na⁺] 375.9347, found 375.9349.

8-Bromo-10-methoxy-2-methyldibenzo[b,f][1,4]oxazepin-11(10H)-one (2k)



Following the general procedure, **2k** was obtained as a tan solid (159 mg), yield: 95%, mp. 119 – 121 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.75 (d, *J* = 1.4 Hz, 1H), 7.66 (d, *J* = 2.3 Hz, 1H), 7.28 (td, *J* = 8.7, 2.0 Hz, 2H), 7.11 (dd, *J* = 8.4, 8.4 Hz, 2H), 3.94 (s, 3H), 2.34 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 162.6, 157.3, 150.4, 135.5, 135.1, 134.2, 132.2, 129.7, 123.5, 123.3, 122.6, 120.1, 118.6, 63.0, 20.6; HRMS (ESI) calcd for C₁₆H₁₄⁷⁹BrNNaO₂⁺ [M + Na⁺] 354.0100, found 354.0101.

3,8-Dichloro-10-methoxydibenzo[b,f][1,4]oxazepin-11(10H)-one (2l)



Following the general procedure, **21** was obtained as a white solid (112 mg), yield: 72%, mp. 132 – 134 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.93 (d, *J* = 8.1 Hz, 1H), 7.53 (s, 1H), 7.27 – 7.23 (m, 2H), 7.19 (d, *J* = 8.5 Hz, 1H), 7.15 (d, *J* = 8.6 Hz, 1H), 3.94 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 161.6, 159.5, 149.0, 140.0, 133.7, 133.3, 131.8, 126.9, 126.1, 122.6, 122.3, 120.8, 120.4, 63.1; HRMS (ESI) calcd for C₁₄H₉³⁵Cl₂NNaO₃⁺ [M + Na⁺] 331.9852, found 331.9850.

8-Chloro-10-methoxy-2-methyldibenzo[b,f][1,4]oxazepin-11(10H)-one (2m)



Following the general procedure, **2m** was obtained as a tan solid (124 mg), yield: 85%, mp. 117 – 119 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.76 (d, *J* = 1.3 Hz, 1H), 7.52 (d, *J* = 2.4 Hz, 1H), 7.29 (dd, *J* = 8.2, 1.6 Hz, 1H), 7.18 (d, *J* = 8.6 Hz, 1H), 7.13 (dd, *J* = 8.6, 2.4 Hz, 1H), 7.09 (d, *J* = 8.2 Hz, 1H), 3.94 (s, 3H), 2.34 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 162.6, 157.4, 149.9, 135.5, 135.1, 134.0, 132.2, 131.2, 126.7, 123.5, 122.2, 120.4, 120.1, 63.0, 20.6; HRMS (ESI) calcd for C₁₅H₁₂³⁵ClNNaO₃⁺ [M + Na⁺] 312.0398, found 312.0401.

10-Methoxy-8-methyldibenzo[*b*,*f*][1,4]oxazepin-11(10*H*)-one (2n)



Following the general procedure, **2n** was obtained as a light yellow oil (76 mg), yield: 59%. ¹H NMR (600 MHz, CDCl₃) δ 7.96 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.48 (ddd, *J* = 9.2, 7.8, 1.7 Hz, 1H), 7.33 (d, *J* = 1.4 Hz, 1H), 7.22 (ddd, *J* = 8.0, 7.5, 3.2 Hz, 2H), 7.14 (d, *J* = 8.2 Hz, 1H), 6.98 (dd, *J* = 8.2, 1.5 Hz, 1H), 3.93 (s, 3H), 2.34 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.7, 159.9, 149.4, 136.0, 134.1, 132.1, 127.6, 125.3, 124.6, 120.8, 120.3, 62.7, 21.0 (two carbon peak was missing due to overlapping); HRMS (ESI) calcd for C₁₅H₁₃NNaO₃⁺ [M + Na⁺] 278.0788, found 278.0791.

<u>10-Methoxy-6,7-dimethyldibenzo[*b*,*f*][1,4]oxazepin-11(10*H*)-one (20)</u>



Following the general procedure, **20** was obtained as a white solid (59 mg), yield: 43%, mp. 117 – 119 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.98 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.48 (td, *J* = 8.2, 1.7 Hz, 1H), 7.31 – 7.18 (m, 3H), 7.01 (d, *J* = 8.3 Hz, 1H), 3.90 (s, 3H), 2.43 (s, 3H), 2.27 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.6, 159.8, 149.9, 136.2, 133.8, 132.2, 130.4, 129.1, 126.6, 125.3, 125.1, 120.6, 117.5, 62.8, 19.8, 12.6; HRMS (ESI) calcd for C₁₆H₁₅NNaO₃⁺ [M + Na⁺] 292.0944, found 292.0941.

9-Methoxybenzo[b]thieno[2,3-f][1,4]oxazepin-10(9H)-one (2p)



Following the general procedure, **2p** was obtained as a tan solid (41 mg), yield: 33%, mp. 123 – 125 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.58 (d, *J* = 8.0 Hz, 1H), 7.51 (d, *J* = 5.3 Hz, 1H), 7.32 – 7.22 (m, 1H), 7.18 (d, *J* = 3.9 Hz, 2H), 6.85 (d, *J* = 5.3 Hz, 1H), 3.89 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 159.9, 150.1, 133.2, 132.3, 126.9, 126.2,

121.1, 120.8, 120.3, 118.8, 62.9 (one carbon peak was missing due to overlapping); HRMS (ESI) calcd for $C_{12}H_9NNaO_3S^+$ [M + Na⁺] 270.0195, found 270.0197.

<u>N-Methoxy-2-(4-nitrophenoxy)-N-(2,2,2-trifluoroethoxy)benzamide (2q)</u>



Following the general procedure, **2q** was obtained as a colorless oil (110 mg), yield: 57%. ¹H NMR (600 MHz, CDCl₃) δ 8.22 (d, *J* = 2.1 Hz, 1H), 8.20 (d, *J* = 2.1 Hz, 1H), 7.58 (m, 2H), 7.35 (td, *J* = 7.6, 0.8 Hz, 1H), 7.11 (d, *J* = 8.1 Hz, 1H), 7.03 – 6.98 (m, 2H), 4.30 (q, *J* = 8.4 Hz, 2H), 3.77 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 170.8 , 161.7 , 151.1 , 142.1 , 132.1 , 128.9 , 125.7 , 125.0 , 124.4 , 121.7 (q, *J* = 272.6 Hz) 120.4 , 116.2 , 69.3 (q, *J* = 34.8 Hz), 60.2; HRMS (ESI) calcd for C₁₆H₁₃¹⁹F₃N₂NaO₆⁺ [M + Na⁺] 409.0618, found 409.0621.

3-Methylspiro[benzo[e][1,3]oxazine-2,1'-cyclohexa[2,5]diene]-4,4'(3H)-dione (2r)



Following the general procedure, **2r** was obtained as a yellow solid (85 mg), yield: 66%, mp. 103 – 105 °C. ¹H NMR (600 MHz, CDCl₃) δ 8.01 (d, *J* = 6.9 Hz, 1H), 7.53 (t, *J* = 6.9 Hz, 1H), 7.19 (t, *J* = 6.5 Hz, 1H), 7.01 (d, *J* = 9.8 Hz, 2H), 6.97 (d, *J* = 7.8 Hz, 1H), 6.39 (d, *J* = 9.7 Hz, 2H), 3.88 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 183.9, 162.6, 154.0, 140.2, 135.6, 131.7, 128.2, 123.4, 117.1, 116.3, 86.9, 65.5; HRMS (ESI) calcd for C₁₄H₁₁NNaO₄⁺ [M + Na⁺] 280.0580, found 280.0577.

V. References:

(a) T. Akbarzadeh, S. A. Tabatabai, M. J. Khoshnoud, B. Shafaghic and A. Shafieea, *Bioorg. Med. Chem.*, 2003, **11**, 769. (b) M. J. Assarzadeh, A. Almasirad, A. Shafiee, M. N. Koopaei and M. Abdollahi, *Med. Chem. Res.*, 2014, **23**, 948.
(a) R. Giri, J. R. Goodell, C. Xing, A. Benoit, H. Kaur, H. Hiasa and D. M. Ferguson, *Bioorg. Med. Chem.*, 2010, **18**, 1456. (b) R. Arundhathi, D. Damodara, A.

- P. R. Likhar, M. L. Kantam, P. Saravanan, T. Magdaleno and S. H. Kwonc, *Adv. Synth. Catal.*, 2011, **353**, 1591.
- 3. Anderson, M. O.; Jamie, M.; John, S.; and Guy, R. K. Synlett 2004, 13, 2391.
- 4. D. K. Chalmers, G. H. Scholz, D. J. Topliss, E. Kolliniatis, S. L. A. Munro, D. J.

Craik, M. N. Iskander and J. R. Stockigt, J. Med. Chem., 1993, 36, 1272.



























S26












S32

















S39





















1.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 f1 (ppm)




















































































S84

















